BioMedNewsBreaks Archive - Page 48 of 224

TuesdayMay 14, 2024 4:10 pm

BioMedNewsBreaks — Rejuvine Life Sciences Launches Crowdfunding Campaign

Rejuvine Life, dedicated to developing natural healthcare solutions, today announced a crowdfunding campaign to expand its U.S. product line and advance diabetes research management. According to the announcement, the company utilizes natural resources to support the millions worldwide living with diabetes. Skordo Plus, Rejuvine Life’s leading product, is a garlic-based supplement designed to help regulate blood sugar levels and enhance overall well-being. “We believe everyone deserves access to safe and effective healthcare solutions,” said Pat Theenathayalan, CEO of Rejuvine Life Sciences. “This crowdfunding campaign is a chance for individuals passionate about health to join us in making a significant impact…

TuesdayMay 14, 2024 3:24 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation Schedule for Upcoming May Conferences

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced that it will participate in three investor conferences in May. Clene will participate in one-on-one meetings at the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference. See the announcement for more information, including dates and locations of the events. To view the full press release, visit https://ibn.fm/P7S2v About Clene Inc. Clene (along with its…

TuesdayMay 14, 2024 3:12 pm

BioMedNewsBreaks – Scorpius Holdings Inc. (NYSE American: SCPX) Announces Pricing of Underwritten Public Offering

Scorpius (NYSE American: SCPX), an integrated contract development and manufacturing organization (“CDMO”), has announced the pricing of its underwritten public offering of 60,000,000 common units and/or pre-funded units in lieu thereof. Each common (or pre-funded) unit is being offered at a public offering price of $0.10 (inclusive of the pre-funded warrant exercise price) and consists of one share of common stock (or pre-funded warrant to purchase one share of common stock in lieu thereof) and a common warrant to purchase one share of common stock. The common warrants will have an exercise price of $0.12 per share and will be…

TuesdayMay 14, 2024 2:27 pm

BioMedNewsBreaks — Astrotech Corp. (NASDAQ: ASTC) Releases Q3 202 Financial Report

Astrotech (NASDAQ: ASTC), an innovative science and technology company, is reporting its financial results for the third quarter of fiscal year 2024, for the period ended March 31, 2024. Highlights of the report include the company’s strong consolidated balance sheet showing $34.7 million in cash and liquid investments; revenue for the year-to-date coming in at $1.6 million; year-to-date gross margin increased to 45% from 37% through the third quarter of fiscal year 2024; the company’s subsidiary, 1st Detect, accepting orders for the TRACER 1000 Narcotics Trace Detector (“NTD”); the TRACER 1000 being listed in the U.S. General Services Administration (“GSA”) IT…

TuesdayMay 14, 2024 8:30 am

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports ‘Extremely Significant Results in HV-387 Animal Study Treating RSV

NanoViricides (NYSE American: NNVC), a global leader in broad-spectrum antiviral nanomedicines, is reporting that the antiviral activity of its lead candidate, NV-387, against RSV/A2 is “strong enough to have resulted in full survival of lethally infected animals.” According to the announcement, the company conducted a study that involved extended dosing of NV-387 given orally; those results were compared with a high oral dose of ribavirin, the current approved treatment for RSV, given for the same period. Following this dosing regimen, the NV-387 resulted in complete survival of the mice beyond the 21-day study period, with no signs of pathology (disease)…

MondayMay 13, 2024 11:47 am

BioMedNewsBreaks — HeartBeam Inc.’s (NASDAQ: BEAT) AIMIGo(TM) Recognized as ‘Best New ECG Technology Solution’ in Awards Program

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced that its HeartBeam AIMIGo(TM) was selected as winner of the “Best New ECG Technology Solution” award in the 8th annual MedTech Breakthrough Awards program. Conducted by MedTech Breakthrough, an independent market intelligence organization, the awards program recognizes the top companies, technologies and products in the global digital health and medical technology market. “The ‘Best New ECG Technology Solution’ award from MedTech Breakthrough is a reflection of our commitment to provide patients and physicians with the ability to accurately monitor cardiac…

FridayMay 10, 2024 2:12 pm

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Featured in Upcoming RedChip Small, Big Money(TM) Show

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is featured in an upcoming interview on the RedChip Small Stocks, Big Money(TM) show. During the program, which is scheduled to air on Bloomberg TV this Saturday, May 11, at 7 p.m. ET, Gareth Sheridan, Founder and CEO of Nutriband, will provide a corporate update. To access the interview, visit https://ibn.fm/Nhihy To view the full press release, visit https://ibn.fm/sLj8d About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Its lead product under development is an abuse deterrent fentanyl patch…

FridayMay 10, 2024 10:36 am

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q1 2024 Financial, Operational Report

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, is reporting on its financial and operational results for first quarter 2024, for the period ended March 31, 2024. Highlights of the report include the 510(k) submission for BEAT’s AIMIGo(TM) system for review by the U.S. Food and Drug Administration (“FDA”); presubmission meetings being held with the FDA in preparation to submit a second 510(k) for BEAT’s 12-lead synthesis software; beginning patient enrollment for a study designed to demonstrate the similarity between the synthesized 12-lead ECG and a standard 12-lead ECG; the presentation…

ThursdayMay 09, 2024 3:47 pm

BioMedNewsBreaks — Astrotech Corporation (NASDAQ: ASTC) Filling Void in Hemp and Cannabis Market

Astrotech (NASDAQ: ASTC), a science and technology development and commercialization company, and its wholly owned subsidiary, AgLAB Inc., have developed a mass spectrometer designed for use in the hemp and cannabis market. “During the process of converting cannabis biomass into distillate, valuable cannabinoids are typically lost, resulting in reduced profits. AgLAB’s Maximum Value Processing (‘MVP’) method uses the powerful AgLAB-1000-D2 mass spectrometer to test and to accurately configure the distillation system for optimal efficiency. The AgLAB MVP mass spectrometer and its rugged design are built to withstand the demands of the factory floor. The AgLAB-1000-D2 model offers real-time potency tests…

WednesdayMay 08, 2024 1:27 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation Highlights

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., are reporting on first-quarter 2024 financial results and operating highlights for its CNM-Au8 clinical program for amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). Clene Nanomedicine is a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases. Highlights of the report include the news that data from the long-term extension of Clene’s phase 2 VISIONARY-MS clinical trial of CNM-Au8® exhibits significant evidence of repair and remyelination across multiple paraclinical endpoints; the publication of an article in the “ACS Pharmacology & Translational Science,” a journal that publishes…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

BioMedNewsBreaks

BioMedNewsBreaks — Rejuvine Life Sciences Launches Crowdfunding Campaign

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Announces Participation Schedule for Upcoming May Conferences

BioMedNewsBreaks – Scorpius Holdings Inc. (NYSE American: SCPX) Announces Pricing of Underwritten Public Offering

BioMedNewsBreaks — Astrotech Corp. (NASDAQ: ASTC) Releases Q3 202 Financial Report

BioMedNewsBreaks — NanoViricides (NYSE American: NNVC) Reports ‘Extremely Significant Results in HV-387 Animal Study Treating RSV

BioMedNewsBreaks — HeartBeam Inc.’s (NASDAQ: BEAT) AIMIGo(TM) Recognized as ‘Best New ECG Technology Solution’ in Awards Program

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Featured in Upcoming RedChip Small, Big Money(TM) Show

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Q1 2024 Financial, Operational Report

BioMedNewsBreaks — Astrotech Corporation (NASDAQ: ASTC) Filling Void in Hemp and Cannabis Market

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Releases Q1 2024 Financial Numbers, Operation Highlights

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search